Inozyme Pharma Dirección

Dirección controles de criterios 2/4

El CEO de Inozyme Pharma's es Doug Treco , nombrado en Apr 2023, tiene una permanencia de 1.17 años. compensación anual total es $5.30M, compuesta por 7.1% salario y 92.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.033% de las acciones de la empresa, por valor de $95.06K. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 6.2 años, respectivamente.

Información clave

Doug Treco

Chief Executive Officer (CEO)

US$5.3m

Compensación total

Porcentaje del salario del CEO	7.1%
Permanencia del CEO	1.2yrs
Participación del CEO	0.03%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	6.2yrs

Actualizaciones recientes de la dirección

Recent updates

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Doug Treco en comparación con los beneficios de Inozyme Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$77m
Dec 31 2023	US$5m	US$375k	-US$71m
Sep 30 2023	n/a	n/a	-US$68m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$106k	n/a	-US$67m
Sep 30 2022	n/a	n/a	-US$67m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$62m
Dec 31 2021	US$188k	n/a	-US$57m
Sep 30 2021	n/a	n/a	-US$49m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$339k	n/a	-US$56m

Compensación vs. Mercado: La compensación total de Doug($USD5.30M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.58M).

Compensación vs. Ingresos: La compensación de Doug ha aumentado mientras la empresa no es rentable.

CEO

Doug Treco (66 yo)

1.2yrs

Permanencia

US$5,299,476

Compensación

Dr. Douglas A. Treco, also known as Doug, Ph.D. is a Scientific Advisor at LSV Capital Management LLC. He was Chief Executive Officer of Alchemab Therapeutics from April 2021 to April 2022. Dr. Treco co-fo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Douglas Treco	CEO & Chairman	1.2yrs	US$5.30m	0.033% $ 92.0k
Axel Bolte	Co-Founder	no data	US$1.80m	0.43% $ 1.2m
Sanjay Subramanian	Senior VP	2.3yrs	US$1.03m	0.049% $ 135.3k
Matthew Winton	Senior VP & COO	1.2yrs	US$1.55m	0.0052% $ 14.2k
Demetrios Braddock	Co-Founder	no data	sin datos	sin datos
Soojin Kim	Senior VP & Chief Technical Operations Officer	2.3yrs	sin datos	sin datos
David Thompson	Senior VP	1.3yrs	sin datos	sin datos
Stefan Riley	Director of Investor Relations	no data	sin datos	sin datos
Gayle Gironda	Senior VP & Chief People Officer	2.9yrs	sin datos	sin datos
Yves Sabbagh	Chairman of Scientific Advisory Board & Senior VP	no data	sin datos	sin datos
Stephen J. Palma	Consultant	2.3yrs	sin datos	sin datos
Kurt Gunter	Senior VP & Chief Medical Officer	2yrs	sin datos	sin datos

2.1yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de INZY se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Douglas Treco	CEO & Chairman	4.1yrs	US$5.30m	0.033% $ 92.0k
Axel Bolte	Co-Founder	8.8yrs	US$1.80m	0.43% $ 1.2m
Demetrios Braddock	Co-Founder	no data	sin datos	sin datos
Yves Sabbagh	Chairman of Scientific Advisory Board & Senior VP	no data	sin datos	sin datos
Martin Edwards	Independent Director	6.8yrs	US$129.65k	0% $ 0
Reinaldo Diaz	Lead independent director	7.4yrs	US$130.27k	0% $ 0
Joseph Schlessinger	Member of Scientific Advisory Board	no data	US$135.00k	sin datos
Edward Mathers	Independent Director	7.4yrs	US$116.15k	0% $ 0
Robert Hopfner	Independent Director	5.6yrs	US$112.15k	0% $ 0
Sarah Bhagat	Independent Director	5.3yrs	US$114.65k	0% $ 0
Lynne Sullivan	Independent Director	4.1yrs	US$122.15k	0% $ 0
Michael Levine	Chairperson of Clinical Advisory Board	no data	sin datos	sin datos

6.2yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de INZY se considera experimentada (6.2 años de antigüedad promedio).

Inozyme Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

CEO & Chairman exercised options and sold US$52k worth of stock

Insufficient new directors

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Inozyme Pharma, Inc. Announces Management Changes

High number of new directors

Recent updates

New major risk - Revenue and earnings growth

Price target decreased by 7.5% to US$19.43

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency

CEO & Chairman exercised options and sold US$52k worth of stock

New minor risk - Share price stability

Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency

New major risk - Revenue and earnings growth

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions

Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

New minor risk - Share price stability

Price target decreased by 9.3% to US$20.50

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.5% to US$22.60

Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701

Insufficient new directors

Price target decreased by 13% to US$19.17

Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

Price target increased by 8.5% to US$21.80

Inozyme Pharma, Inc. Provides Business Updates

Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

Price target increased to US$23.20

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Index

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Price target decreased to US$29.40

Inozyme Pharma, Inc. Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Price target decreased to US$30.00

Inozyme Pharma, Inc. Announces Management Changes

High number of new directors

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Price target decreased to US$32.25

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Growth Index

President exercised options and sold US$65k worth of stock

Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of Inz-701 in Abcc6 Deficiency

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Senior Vice President of Finance Stephen Basso has left the company

Inozyme Pharma, Inc. Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

New 90-day low: US$19.96

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Inozyme Pharma Announces Executive Changes

Senior VP & Chief Medical Officer has left the company

New 90-day high: US$27.90

Inozyme Pharma, Inc. Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Inozyme Pharma EPS misses by $1.02

Inozyme Pharma Appoints Kevin B. Johnson as Senior Vice President, Regulatory Affairs

Inozyme Pharma, Inc. Announces Executive Changes

Inozyme Pharma, Inc. has completed an IPO in the amount of $112 million.

Análisis de compensación del CEO